CCM
CRBP icon

Chilton Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Chilton Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273 Buy
+29
New +$275 ﹤0.01% 582

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Chilton Capital Management's CRBP Position: Q2 2026 in Review

Chilton Capital Management opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 29 shares worth $273. The stake represents ﹤0.01% of the portfolio and ranks #582 among its holdings.

107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Chilton Capital Management held 29 shares of Corbus Pharmaceuticals worth $273 as of Q2 2026.
  • Corbus Pharmaceuticals was a new Chilton Capital Management position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Chilton Capital Management's portfolio in Q2 2026, its #582 holding.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.